DBV Technologies (DBVT) Other Non-Current Liabilities (2015 - 2025)
DBV Technologies (DBVT) reported Other Non-Current Liabilities of $8.4 million for Q3 2025, up 8.52% year-over-year from $7.8 million in Q3 2024, and up 12.38% quarter-over-quarter from $7.5 million in Q2 2025.
DBV Technologies (DBVT) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
DBV Technologies (DBVT) has 11 years of Other Non-Current Liabilities data on file, last reported at $8.4 million in Q3 2025.
- Other Non-Current Liabilities for Q3 2025 came in at $8.4 million, up 8.52% year-over-year; the trailing twelve-month figure through Sep 2025 was $8.4 million (up 8.52% YoY), and the FY2024 annual result was $8.3 million, down 6.78% from the prior year.
- Other Non-Current Liabilities improved to $8.4 million in Q3 2025 per DBVT's latest filing, from $7.5 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $17.0 million in Q3 2021 and troughed at $979000.0 in Q3 2022.
- A 5-year average of $6.2 million and a median of $5.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2022: Other Non-Current Liabilities surged 352.0% in 2021, then slumped 94.22% in 2022.
- A 5-year view of Other Non-Current Liabilities shows it stood at $2.1 million in 2021, then surged by 120.54% to $4.7 million in 2022, then surged by 88.68% to $8.9 million in 2023, then decreased by 6.78% to $8.3 million in 2024, then rose by 1.45% to $8.4 million in 2025.
- Business Quant data shows DBVT's Other Non-Current Liabilities at $8.4 million in Q3 2025, $7.5 million in Q2 2025, and $5.4 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 8.33 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 2.70 Mn |
| Jun 30, 2023 | 11.25 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 4.74 Mn |
| Sep 30, 2022 | 979,000.00 |
| Jun 30, 2022 | 10.54 Mn |
| Mar 31, 2022 | 1.46 Mn |
| Dec 31, 2021 | 2.15 Mn |
| Sep 30, 2021 | 16.95 Mn |
| Jun 30, 2021 | 3.47 Mn |
| Mar 31, 2021 | 1.29 Mn |
| Dec 31, 2020 | 475,000.00 |
| Dec 31, 2019 | 1.63 Mn |